Cash from Financing (Quarterly) Chart

View Cash from Financing (Quarterly) for ZNTL.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash from Financing (Quarterly) Chart
Start Trial

Historical Cash from Financing (Quarterly) Data

View and export this data back to 2019. Start Trial.
Date Value
June 30, 2026 0.065M
March 31, 2026 -1.123M
December 31, 2025 -4.586M
September 30, 2025 0.115M
June 30, 2025 0.00
March 31, 2025 0.189M
December 31, 2024 0.00
September 30, 2024 0.092M
June 30, 2024 0.009M
March 31, 2024 0.007M
December 31, 2023 0.00
September 30, 2023 0.309M
June 30, 2023 236.62M
March 31, 2023 0.373M
December 31, 2022 49.74M
Date Value
September 30, 2022 0.589M
June 30, 2022 209.46M
March 31, 2022 1.258M
December 31, 2021 12.27M
September 30, 2021 166.57M
June 30, 2021 -0.316M
March 31, 2021 0.00
December 31, 2020 -0.594M
September 30, 2020 155.90M
June 30, 2020 173.24M
March 31, 2020 13.47M
December 31, 2019 -0.053M
September 30, 2019 81.88M
June 30, 2019 0.00
March 31, 2019 0.00

Cash From Financing Definition

Represents the net cash flow resulting from the company's financing activities. Financing activities represent movement in the company's debt and share capital and other activities.

Read full definition.

Cash from Financing (Quarterly) Range, Past 5 Years

View Cash from Financing (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Financing (Quarterly) Benchmarks

View Cash from Financing (Quarterly) Benchmarks
Start Trial
ARS Pharmaceuticals, Inc. 3.197M
ACADIA Pharmaceuticals, Inc. 10.49M
Alnylam Pharmaceuticals, Inc. 36.24M
Anika Therapeutics, Inc. -0.701M
Savara, Inc. 0.189M